Last reviewed · How we verify
Integrilin (EPTIFIBATIDE)
Integrilin blocks the binding of fibrinogen to platelets, preventing them from clumping together and forming clots.
Integrilin (Eptifibatide) is a small molecule platelet aggregation inhibitor that targets the integrin alpha-IIb/beta-3 receptor. It is a generic, off-patent medication approved by the FDA in 1998 for the treatment of acute coronary syndrome, non-Q wave myocardial infarction, percutaneous coronary intervention, and unstable angina. As a platelet aggregation inhibitor, Integrilin works by blocking the binding of fibrinogen to the integrin alpha-IIb/beta-3 receptor, thereby preventing platelet aggregation and clot formation. The medication has a half-life of 4.2 hours and is administered intravenously. With 13 generic manufacturers, Integrilin is widely available and has no active Orange Book patents.
At a glance
| Generic name | EPTIFIBATIDE |
|---|---|
| Sponsor | Merck & Co. |
| Drug class | Platelet Aggregation Inhibitor [EPC] |
| Target | Integrin alpha-IIb/beta-3 |
| Modality | Recombinant protein |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1998 |
Mechanism of action
Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet.
Approved indications
- Acute coronary syndrome
- NonQ wave myocardial infarction
- Percutaneous coronary intervention
- Unstable angina
Common side effects
- Major bleeding
- Minor bleeding
- Requiring transfusions
- Hemorrhagic stroke
- Cerebral infarction
Key clinical trials
- Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis (PHASE3)
- Multi-arm Optimization of Stroke Thrombolysis (PHASE3)
- EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED) (PHASE3)
- Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic (PHASE1,PHASE2)
- Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?
- Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention (PHASE2)
- Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel (PHASE2)
- Eptifibatide in Endovascular Treatment of Acute Ischemic Stroke (EPOCH) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Integrilin CI brief — competitive landscape report
- Integrilin updates RSS · CI watch RSS
- Merck & Co. portfolio CI